Work

A phase I/II study of CDX-1140, a CD40 agonist, in combination with capecitabine and oxaliplatin (CAPOX) and pembrolizumab in subjects with biliary tract carcinoma: Phase 1 results.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4129

Authors: Tim F. Greten, Donna Mabry Hrones, Cecilia Monge, Nebojsa Skorupan, David E. Kleiner, Bradford Wood, Bernadette Redd

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162496870

Cites:

Cited by:

Related to: